Working… Menu

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02181660
Recruitment Status : Completed
First Posted : July 4, 2014
Last Update Posted : December 24, 2018
Information provided by (Responsible Party):
Astellas Pharma Inc

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 27, 2016
Actual Study Completion Date : June 27, 2016